In lab and animal studies, BPC 157 is linked to helping keep the proteins that seal the gut lining intact when NSAIDs are present, which may prevent harmful substances from leaking into the body.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of human trials would determine whether BPC 157 administration consistently alters expression or localization of occludin, claudin-2, or ZO-1 in intestinal biopsies of NSAID users compared to placebo.
A systematic review and meta-analysis of all published randomized controlled trials in adults taking NSAIDs for ≥4 weeks, with intestinal biopsies collected pre- and post-treatment, measuring changes in tight junction protein expression (occludin, claudin-2, ZO-1) via immunohistochemistry or Western blot, comparing BPC 157 (oral or subcutaneous, 10 µg/kg/day) to placebo.
An RCT would determine whether BPC 157 causally prevents NSAID-induced disruption of tight junction proteins in human intestinal tissue.
A double-blind, placebo-controlled trial of 60 adults taking daily ibuprofen 600 mg for 14 days, randomized to receive oral BPC 157 (10 µg/kg twice daily) or placebo, with terminal ileal biopsies collected at baseline and day 14, measuring changes in occludin, claudin-2, and ZO-1 protein expression via Western blot and localization via immunofluorescence.
A prospective cohort would determine whether individuals taking BPC 157 alongside NSAIDs show slower decline in tight junction protein expression over time compared to non-users.
A prospective cohort study following 200 patients with chronic arthritis on long-term NSAIDs, with serial intestinal biopsies (baseline, 6, 12 months) and BPC 157 use tracked, measuring changes in occludin and claudin-2 expression, adjusting for NSAID dose, PPI use, and smoking.
A case-control study would assess whether patients with NSAID-induced mucosal injury have lower levels of tight junction proteins compared to those without injury, and whether BPC 157 use is associated with higher levels.
A case-control study comparing 50 patients with confirmed NSAID-induced small bowel ulcers (via capsule endoscopy) to 100 matched controls without ulcers, measuring occludin and claudin-2 expression in terminal ileal biopsies and retrospectively assessing prior BPC 157 use.
A cross-sectional study would identify whether individuals currently using BPC 157 have higher tight junction protein expression in intestinal biopsies than non-users at a single time point.
A cross-sectional analysis of 100 adults on chronic NSAIDs undergoing routine endoscopy, comparing occludin and claudin-2 expression in terminal ileal biopsies between those currently using BPC 157 (≥30 days) and those not using it, adjusting for age, NSAID type, and duration.